Dr. Miele Cosmed Group S.A. (DMG) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Dr. Miele Cosmed Group S.A. stock PLN 4.05, price PLN 1.85, upside +119.5%, quality 54 out of 100. Rating: strongly undervalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 1.81 PLN – 5.34 PLN · fair‑value band 2.78 PLN – 6.03 PLN · the 1.85 PLN price screens below the 4.05 PLN fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Dr. Miele Cosmed Group in your weekly email
Every Wednesday you see whether Dr. Miele Cosmed Group is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Dr. Miele Cosmed Group S.A. engages in the production and sale of chemical and cosmetic assortments in Poland and internationally.
Show moreShow less
The company offers washing and care cosmetics, wet wipes, and laundry detergents for children; cleansing cosmetics, such as sanitizing gels and sprays, and liquid soaps; shower gels; and toilet cleaners, toilet blocks, and drain opener granules and gels; washing liquids and fabric softening concentrates; cleaning agents for kitchens and bathrooms; and hand sanitizing and surface disinfectants.
The company markets its products primarily under the Bobini, Apart, Biophen, Mole, Sofin, Izo, and Izozid brands. The company was formerly known as Global Cosmed S.A. and changed its name to Dr. Miele Cosmed Group S.A. in March 2024. The company was founded in 1990 and is based in Radom, Poland.
Stock analysis
Dr. Miele Cosmed Group S.A. (DMG) currently trades at 1.85 PLN, while our model-based Fair Value estimate is 4.05 PLN, implying the stock looks roughly 54% undervalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 4.93 PLN per share, and 23 of the 26 models we run sit above the 1.85 PLN price.
Bear case: the Dividend Discount group reads lowest at 0.8450 PLN, and 3 of the 26 models stay below the price. Data coverage for this calculation is low.
Scenario range: 2.78 PLN (bear) to 6.03 PLN (bull), the price of 1.85 PLN sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 54/100 (solid quality), in the Consumer Defensive sector.
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Dr. Miele Cosmed Group S.A. reported revenue of 504M PLN in FY2025 versus 352M PLN in FY2021, a compound +9.4%/yr. Reported net income was 19.7M PLN in FY2025, compounding +14.2%/yr from FY2021.
Key figures
Market cap 158M PLN (≈ $40.4M) Micro · P/E ratio 12.3 · P/S ratio 0.32 · EPS (TTM) 0.1500 PLN · Dividend yield 4.3% · Net margin 2.5% · Return on equity 4.6% · Return on assets (EBIT) 6.4% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 34 out of 100 (low confidence).
What moves the price
The share trades about 42% below its 52-week high and 1% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at −26% fair-value upside, at 120%, DMG screens cheaper than that median.
Fair Value models
Bear2.78 PLNFair Value 4.05 PLNBull6.03 PLN
Price 1.85 PLN · Upside +119.5%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2025 figures (about 10 months old). Earnings retained since then (0.0600 PLN per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.68/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+3.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+8.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.7%
Start year 2020 (pandemic). Over 10 years: +8.3% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.0%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+15.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.5%
Dividend (yield on the price)4.3%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.11.5% vs 3.6%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.9% → 6%
Pace: the 5-year rate starts in 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+3.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Poland: IMF forecast 3.1% a year to 2030, 4.6% from 2016 to 2025) that is about +0.1% a year for the price.
Compare Dr. Miele Cosmed Group S.A. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Household & Personal Products · 230 stocks
Beats the industry median on 7/13 measures
A mixed picture versus its industry peers.
Valuation
Quality Score54 · Below median
Fair Value upside+119.5% · Top 25%
Profitability
Return on equity (12 months)4.6% · Below median
Return on assets4.6% · Below median
Net margin (12 months)2.5% · Below median
Operating margin (12 months)1.5% · Below median
Growth and dividend
Revenue growth (quarter YoY)−2.6% · Below median
Dividend yield (12 months)4.3% · Above median
Valuation Multiplesvs Household & Personal Products median · lower = cheaper
P/E (12 months)12.3× · Cheaper than median
P/B0.59× · Cheapest 25%
P/S (12 months)0.32× · Cheapest 25%
Price / free cash flow (fiscal year)12.2× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Dr. Miele Cosmed Group S.A. Fair Value". https://www.fairvalue-calculator.com/stock/DMG
Frequently asked questions
Is Dr. Miele Cosmed Group S.A. (DMG) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 4.05 PLN versus a price of 1.85 PLN, about +120% upside (undervalued).
What is the fair value of DMG?
Our model-based fair value for Dr. Miele Cosmed Group S.A. is 4.05 PLN (as of Nov 9, 2026), built from audited fundamentals. The current price: 1.85 PLN.
What is the quality score of DMG?
Dr. Miele Cosmed Group S.A. has a Quality Score of 54/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Dr. Miele Cosmed Group S.A. (DMG)?
Our model-based price target is the fair value of 4.05 PLN (as of Nov 9, 2026) from 26 valuation models. Cautious scenario 2.78 PLN, optimistic scenario 6.03 PLN. It is a calculation from audited fundamentals, not an analyst target.
What is the Dr. Miele Cosmed Group S.A. stock forecast for 2026?
Our models put fair value at 4.05 PLN, about +120% upside versus a price of 1.85 PLN (undervalued). Cautious scenario 2.78 PLN, optimistic scenario 6.03 PLN. The calculation is refreshed regularly with new filings.
What is the revenue of Dr. Miele Cosmed Group S.A. (DMG)?
Dr. Miele Cosmed Group S.A. reported trailing-twelve-month revenue of about 496M PLN (latest available figure, as of Nov 9, 2026).
Does Dr. Miele Cosmed Group S.A. pay a dividend?
Dr. Miele Cosmed Group S.A. currently shows a dividend yield of 4.34% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Dr. Miele Cosmed Group S.A. (DMG)?
Dr. Miele Cosmed Group S.A. pays a dividend of 0.08 PLN per share a year, a dividend yield of 4.3%. The payout ratio is 53.3% of earnings. Free cash flow covers the dividend 1.90 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Dr. Miele Cosmed Group S.A. (DMG)?
For today's price to be fair in a discounted-cash-flow model, Dr. Miele Cosmed Group S.A. would have to grow free cash flow by +3.3 % per year for five years (discount rate 9.3 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.7 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of DMG use?
Our models discount Dr. Miele Cosmed Group S.A. at 9.3 %: a base by market capitalisation (nano), damped by beta 0.21, country premium for Poland. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Dr. Miele Cosmed Group S.A. that is +3.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (9.3 %) and the same formula as our fair value.
How much growth has Dr. Miele Cosmed Group S.A. (DMG) delivered so far?
Over the past 5 years revenue at Dr. Miele Cosmed Group S.A. grew +6.7 % a year. The price currently implies free-cash-flow growth of +3.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Dr. Miele Cosmed Group S.A. (DMG) growing?
The median revenue growth in the sector is +2.0 % a year. That is the yardstick for the growth priced into Dr. Miele Cosmed Group S.A. (+3.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Dr. Miele Cosmed Group S.A. (DMG)?
The free-cash-flow yield on the price is 8.22 %: that much free cash flow Dr. Miele Cosmed Group S.A. produces per unit of market value. When it exceeds the discount rate of our models (9.3 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Dr. Miele Cosmed Group S.A. (DMG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Dr. Miele Cosmed Group S.A. it is 4.05 PLN per share (as of Nov 9, 2026), against a price of 1.85 PLN. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Dr. Miele Cosmed Group S.A. stock overvalued or undervalued in 2026?
As of Nov 9, 2026, DMG trades below its calculated fair value: price 1.85 PLN, fair value 4.05 PLN, a gap of about +120% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DMG?
No. The price is what the market pays today (1.85 PLN); the fair value is what the company's own numbers justify (4.05 PLN). For Dr. Miele Cosmed Group S.A. the two are 2.21 PLN per share apart. That gap is exactly why we show both numbers side by side.
How much is Dr. Miele Cosmed Group S.A. worth?
The market values Dr. Miele Cosmed Group S.A. at about 158M PLN (market capitalisation, as of Nov 9, 2026). Per share that is 1.85 PLN; our models calculate a fair value of 4.05 PLN per share.
What do the bullish and bearish scenarios say about DMG?
Our models span a range for Dr. Miele Cosmed Group S.A.: cautious scenario 2.78 PLN, base 4.05 PLN, optimistic 6.03 PLN per share (as of Nov 9, 2026, price 1.85 PLN). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of DMG?
Dr. Miele Cosmed Group S.A. trades at a price-to-earnings ratio of 12.3 (as of Nov 9, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 4.05 PLN is built from several models across several years. Median P/E at fiscal year-end, 6 fiscal years (2019 to 2025), reported earnings: 13.1. Other multiples: P/B 0.6, P/S 0.3, EV/EBITDA 5.1.
How solid is the balance sheet of Dr. Miele Cosmed Group S.A. (DMG)?
Balance-sheet figures for Dr. Miele Cosmed Group S.A. (as of Nov 9, 2026): return on equity 4.6%. They feed the Quality Score of 54/100, which measures business quality independently of the share price.
How far is DMG from its 52-week high?
Dr. Miele Cosmed Group S.A. trades at 1.85 PLN, about 42% below its 52-week high of 3.19 PLN and 1% above the low of 1.84 PLN (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 4.05 PLN is for.
Which stocks are comparable to Dr. Miele Cosmed Group S.A.?
From the same area (Consumer Defensive) we also value Colgate-Palmolive Company, Hindustan Unilever Limited, The Estée Lauder Companies Inc, Henkel AG, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Dr. Miele Cosmed Group S.A. stock attractive at the current price?
The data as of Nov 9, 2026: price 1.85 PLN, calculated fair value 4.05 PLN (+120%), Quality Score 54/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of DMG calculated?
We run Dr. Miele Cosmed Group S.A. through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 4.05 PLN builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Dr. Miele Cosmed Group S.A. currently trades 54% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Dr. Miele Cosmed Group S.A. (DMG)?
The closing price on Nov 6, 2026 was 1.85 PLN. Our model-based fair value is 4.05 PLN, about +120% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Dr. Miele Cosmed Group S.A. right now?
The price is below even our cautious bear case (2.78 PLN). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (54/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (2.78 PLN to 6.03 PLN) leaves room in how you read the outcome.
Where does the earnings growth of Dr. Miele Cosmed Group S.A. (DMG) come from?
Earnings per share at Dr. Miele Cosmed Group S.A. grew +9.2 % a year from 2014 to 2025. Broken into its drivers: revenue per share +3.9 %, EBIT margin +6.6 %, tax rate +0.1 %, residual (interest, one-offs) −1.5 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Dr. Miele Cosmed Group S.A.
How large is the market capitalisation of Dr. Miele Cosmed Group S.A. (DMG)?
The market capitalisation of Dr. Miele Cosmed Group S.A. is 158M PLN (≈ $40.4M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Dr. Miele Cosmed Group S.A. (DMG)?
The price-to-sales ratio of Dr. Miele Cosmed Group S.A. is 0.32 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Dr. Miele Cosmed Group S.A. (DMG)?
Earnings per share at Dr. Miele Cosmed Group S.A. are 0.1500 PLN (price ÷ EPS = P/E 12.3). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Dr. Miele Cosmed Group S.A. (DMG)?
The dividend yield of Dr. Miele Cosmed Group S.A. is 4.3% (payout 53.3%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Dr. Miele Cosmed Group S.A. (DMG)?
The net margin of Dr. Miele Cosmed Group S.A. is 2.5% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Dr. Miele Cosmed Group S.A. (DMG)?
The return on equity (ROE) of Dr. Miele Cosmed Group S.A. is 4.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Dr. Miele Cosmed Group S.A. (DMG)?
On an EBIT basis the return on assets of Dr. Miele Cosmed Group S.A. is 6.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Dr. Miele Cosmed Group S.A. (DMG)?
The operating margin of Dr. Miele Cosmed Group S.A. is 1.5% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Dr. Miele Cosmed Group S.A. (DMG)?
Revenue at Dr. Miele Cosmed Group S.A. is growing −2.6% versus a year earlier (3y avg +8.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Dr. Miele Cosmed Group S.A. (DMG)?
Earnings per share at Dr. Miele Cosmed Group S.A. are growing −92.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Dr. Miele Cosmed Group S.A. (DMG) carry?
The net debt of Dr. Miele Cosmed Group S.A. is 37.5M PLN (fiscal year 2025, ≈ 2.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Dr. Miele Cosmed Group S.A. in the live analysis
One click puts Dr. Miele Cosmed Group S.A. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Thin data
Nov 9, 2026